Влияние эпиталона на состояние иммунитета у больных при ожоговой болезни
n = 92 humansNon-randomized comparison of standard therapy vs standard therapy plus epitalon at two doses; randomization and blinding not describedImmunoglobulins measured on days 2, 10 and 20 after injury; epitalon given for 5 days
In 92 burn patients (Chita burn centre), adding intramuscular epitalon to standard care was followed by higher serum immunoglobulins and lower reported mortality (40.4% standard care vs 34.6% and 14.2% in two epitalon groups); no randomization or blinding described, small groups, so inconclusive.
Key resultMortality was 40.4% with standard therapy, 34.6% with epitalon 10 mcg and 14.2% with epitalon 20 mcg; IgM on day 10 was 4.1 and 3.9 times higher in the epitalon groups
- Studied
- Patients aged 15-69 with burns over 5-85% of body surface, Chita regional burn centre
- Compared with
- Standard (conventional) therapy
- Main outcome
- Serum immunoglobulins A, M, G; complications; mortality
- Sample
- 92 burn patients in 3 groups (52 standard care, 26 epitalon 10 mcg, 14 epitalon 20 mcg)
- Authors' conclusion
- The authors concluded epitalon is promising for restoring immune function in burn disease and reducing complications.
- Limitations
- Unequal group sizes, no randomization or blinding described, no statistics beyond 'significant' wording; small dose groups.
